The stress-responsive transforming growth factor-beta-related cytokine, growth-differentiation factor-15 (GDF-15), is emerging as a new biomarker in patients with cardiovascular disease.
The circulating levels of GDF-15 are elevated and independently related to an adverse prognosis in acute coronary syndrome and left- or right-sided heart failure. GDF-15 adds significant prognostic information to established clinical and biochemical risk markers in these conditions.
Elevated levels of GDF-15 may identify patients who have non-ST-elevation acute coronary syndrome who derive the greatest benefit from an invasive treatment strategy. As with other heart failure biomarkers, including BNP, it is currently not known what specific therapies could be used to reduce the risk associated with elevated levels of GDF-15 in heart failure.
Further elucidation of the pathobiology and upstream inducers of this new biomarker may lead to new therapeutic concepts that address the risk associated with elevated GDF-15 levels. A commercial assay for GDF-15 should be available in the near future.
Growth-differentiation factor-15 in heart failure
Kempf T, Wollert KC
Heart Fail Clin. 2009 Oct ; 5(4): 537-47 (Hubmed.org)
Related:
New strategies to improve treatment and ultimately prevent heart ...
The circulating levels of GDF-15 are elevated and independently related to an adverse prognosis in acute coronary syndrome and left- or right-sided heart failure. GDF-15 adds significant prognostic information to established clinical and biochemical risk markers in these conditions.
Elevated levels of GDF-15 may identify patients who have non-ST-elevation acute coronary syndrome who derive the greatest benefit from an invasive treatment strategy. As with other heart failure biomarkers, including BNP, it is currently not known what specific therapies could be used to reduce the risk associated with elevated levels of GDF-15 in heart failure.
Further elucidation of the pathobiology and upstream inducers of this new biomarker may lead to new therapeutic concepts that address the risk associated with elevated GDF-15 levels. A commercial assay for GDF-15 should be available in the near future.
Growth-differentiation factor-15 in heart failure
Kempf T, Wollert KC
Heart Fail Clin. 2009 Oct ; 5(4): 537-47 (Hubmed.org)
Related:
New strategies to improve treatment and ultimately prevent heart ...
Growth of the heart during development is characterized by the differentiation and proliferation of beating cardiac muscle cells. After birth there is a transition which limits the ability of the heart to regenerate itself following ...Use of B-type Natriuretic Peptide to Diagnose Congestive Heart ...
This paper explains the background and current use of B-type natriuretic peptide (BNP) assays to differentiate congestive heart failure (CHF) from other causes of dyspnea. With a large and growing elderly population, ... the AHA lists it as the leading cause of hospitalization among the elderly.5 This fact is important when you consider that by the year 2010 the growth rate of older Americans is expected to be as much as 3.5 times greater than the general population.7 ...Congestive Heart Failure (CHF) | Nursing Crib
It is clinically difficult to differentiate right from left ventricular failure. Failure of one chamber causes reciprocal changes in the opposite chamber. b. Weakness and fatigue. c. Poor feeding, resulting in weight loss. d. Developmental delays. e. Irritability ... Promote optimal growth and development. 9. As appropriate, refer the family to a community health nurse for follow up care after discharge. Nursing Care plan – Congestive Heart Failure. Source: ...
